Agilent acquires AI pathology startup Proscia for $240M cash

Agilent Technologies has agreed to acquire Proscia, a Philadelphia-based AI pathology startup, for $240 million in cash. The deal includes an additional earn-out tied to performance milestones, bringing the total potential value higher.

Proscia, which has been developing AI-powered software for years, focuses on pathology record search and diagnosis, helping labs analyze tissue samples digitally. Its platform is used by clinical labs and research institutions to streamline workflows and improve diagnostic consistency. Agilent, a lab equipment manufacturer, plans to integrate Proscia’s technology into its existing products, though details about how this will work remain unclear.

The acquisition fits a pattern of lab equipment suppliers bringing AI startups into their operations. Similar moves have happened recently, with larger players in the space adding software capabilities to their hardware. Proscia’s deal, while smaller than some others, follows the same approach: combining AI-driven tools with lab equipment to offer more complete solutions.

While Proscia hadn’t raised much venture funding, its acquisition price suggests it had gained traction. The company’s software is used by multiple health systems, though exact figures haven’t been shared. The deal also highlights how AI is becoming more important in pathology, where manual slide review can be slow and inconsistent.

The deal is expected to close in the coming months, pending regulatory approvals. No major changes to Proscia’s team or operations have been announced, though integration plans will likely shape its future direction.

Sources: msn.com